Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Affomix to provide antibodies for Kalgene’s companion diagnostics program
February 2010
SHARING OPTIONS:

BRANFORD, Conn.—Affomix Corp., a developer of automated, high-throughput monoclonal antibody selection technology, announced in late December that it will use its Y2HExpress technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer for Kalgene Pharmaceuticals Inc., a private company focused on the development of oncology therapeutics and companion diagnostics. Under the agreement, Affomix will use Y2HExpress for the selection of single-chain antibodies for Kalgene, whose portfolio of oncology products is at various stages in development, from assay development to advanced clinical trials. Financial terms of the service agreement were not disclosed, nor were the financial milestones related to diagnostic and therapeutic applications.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.